Last reviewed · How we verify

NCT06141603

Comparison of Upper and Lower Limb Maximal Exercise Capacities and Muscle Oxygenation in Patients With ILD

Status unknown Last updated 28 December 2023
What this trial tests

trial in Interstitial Lung Disease in 30 participants. Status unknown.

Timeline
25 November 2023
Primary endpoint
28 December 2024
30 December 2024

Quick facts

Lead sponsorGazi University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date25 November 2023
Primary completion28 December 2024
Estimated completion30 December 2024
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Gazi University

Who can join

Adults 18 to 75, any sex, with Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interstitial lung diseases (ILD) are a complex group of diseases that cause significant morbidity and mortality, develop diffuse lung parenchyma and alveolar inflammation, as well as interstitial fibrosis, which refers to more than 200 diseases. Due to restrictive type ventilation disorder and impaired pulmonary gas exchange, pulmonary function has deteriorated in these patients and progressive shortness of breath, fatigue, cough and exercise intolerance are usually observed, which also affects the quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Interstitial Lung Disease

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06141603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing